Companies/CEL-SCI Corporation

Company profile

CEL-SCI Corporation

AMEX: CVM · Healthcare · Biotechnology

PublicHQ Vienna, VACIK 0000725363Reports USD

#970 of 1,394 Healthcare companies by revenuetop-decile growth

EA Score

32D

FH 25DQ 19GM 61SS 64

v0.1 · 65/100 weight · provisional

↑ listing tenure, revenue growth (YoY) · ↓ operating margin, net margin

Methodology →

Revenue TTM

Rev growth YoY (TTM)

-100.0%

Net income (FY)

-$25.4M

Employees

Market cap

$7.8M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$264.0k$264.0k2014

Net income-$25.4M-$25.4M2025

Operating income-$24.8M-$24.8M2025

Total assets$28.2M$28.2M2025

Liabilities$12.2M$12.2M2025

Equity$16.0M$16.0M2025

Revenue trend

FY2013 – FY2014 · USD

$15.0k

FY13

$15.4k

FY13

$113.7k

FY13

$159.6k

FY13

$113.1k

FY14

$67.2k

FY14

$15.9k

FY14

$264.0k

FY14

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

CEL-SCI Corporation booked $264.0k in FY2014 revenue, growing 1559% year over year — faster than 97% of Healthcare companies we track, at a -9624.2% net margin.

Peers · Healthcare

NKGen Biotech, Inc.——COSCIENS Biopharma Inc.43D OSR Holdings, Inc.33D Bolt Biotherapeutics, Inc.39D

Key facts

CEOGeert R. Kersten

SectorHealthcare

IndustryBiotechnology

HeadquartersVienna, VA

ExchangeAMEX: CVM

Employees43

IPO date1983-12-08

Latest filings

DEF 14A2026-07-02 8-K2026-06-16 10-Q2026-05-15 8-K2026-05-14 8-K2026-05-13 10-Q2026-02-17 10-K2025-12-29 8-K2025-11-24

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.